Abstract
A new quinolone antimicrobial agent, grepafloxacin (GPFX), was studied basically and clinically, with the following results.
1) Basic assessment: Minimum inhibitory concentrations (MICs) of GPFX against 559 strains of 12 isolated species from urinary tract infection (UTI) were compared with those of ofloxacin (OFLX), ciprofloxacin (GPFX) and norfloxacin (NFLX). The minimum 90% inhibitory concentrations (MIC90) of GPFX against gram-positive cocci, i. e., Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis and Enterococcus faecium, were generally less than 8μg/ml. GPFX exhibited excellent antibacterial activity in comparison with other antibiotics. On the other hand, the MIC90 of GPFX against gramnegative bacilli were lower than 0.5μg/ml, with the exception of 32μg/ml for Pseudomonas aeruginosa and Serratia marcescens, and 8μg/ml for Enterobacter spp., showing excellent antibacterial activity. The MIC range of GPFX against Chlamydia trachomatis standard strain (D strain) was equivalent to that of a tetracycline preparation.
2) Clinical assessment: GPFX was administered to 3 patients with acute uncomplicated cystitis and 7 patients with complicated UTI. Clinical efficacy as rated by the Japanese UTI Committee criteria was excellent in all 3 patients with acute uncomplicated cystitis, and the efficacy by physician's evaluation was excellent or effective in all 3 patients. Bacteriologically, all 3 strains were eradicated by the treatment. Clinical efficacy was evaluable by the Japanese UTI Committee criteria in 5 of the 7 patients with complicated UTI. According to the evaluation at 5 days after treatment, the result was excellent in 1, good in 3, and poor in 3, and the efficacy rate was 2/5. The patients in whom the result was poor included 2 patients with infection with at least two bacteria including Escherichia coli and P. aeruginosa.
No abnormal changes in clinical laboratory test values or subjective or objective side effects were observed in any of the 10 patients.
